Hepta Unveils First Multi-Omic Atlas of MASH, Linking Liver Pathway Biology to cfDNA Methylation in Blood [Yahoo! Finance]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
FOSTER CITY, Calif., November 10, 2025 BUSINESS WIRE Hepta , a biotechnology company using transformer-based AI to decode the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today announced the creation of an unparalleled multi-omic atlas of metabolic dysfunction–associated steatohepatitis (MASH) in collaboration with Duke University. This work builds on Hepta's expanded cfDNA studies with Mainz University and Akero Therapeutics' Phase 3 clinical trial program, further strengthening the company's partnerships across academic and clinical research. The atlas integrates single-cell and bulk data across hundreds of liver samples, including gene expression, chromatin accessibility, and DNA methylation, paired with cfDNA methylation from matched blood plasma. Presented this week at AASLD's The Liver Meeting , the atlas reveals how coordinated methylation and transcriptional programs drive inflammation and fibrosis and demonstrates that these same mo
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKROBusiness Wire
- Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)PR Newswire
- Akero Therapeutics (AKRO): Examining Valuation After Strong Year-to-Date Share Price Gains [Yahoo! Finance]Yahoo! Finance
AKRO
Earnings
- 8/8/25 - Beat
AKRO
Sec Filings
- 12/3/25 - Form 8-K
- 11/28/25 - Form 4
- 11/26/25 - Form 4
- AKRO's page on the SEC website